Graeme P. Sullivan

Graeme P. Sullivan

Auto-generated profile, based on publicly available information

Graeme P. Sullivan

Molecular Cell Biology Laboratory, Department of Genetics, Smurfit Institute, Trinity College, Dublin 2, Ireland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
GSGraeme P. Sullivan
Graeme P. Sullivan
LFLyndsey Flanagan
Lyndsey Flanagan
DRDaniel Rodrigues
Daniel Rodrigues
TCTríona Ní Chonghaile
Tríona Ní Chonghaile
Venetoclax is a B cell lymphoma 2 (BCL-2)–selective antagonist used to treat chronic lymphocytic leukemia (CLL) and acute myelogenous leukemia (AML). Although this has been a promising therapeutic option for these patients, many of these patients develop resistance and relapsed disease. Here, we summarize the emerging mechanisms of resistance to venetoclax treatment, discuss the promising combination strategies, and highlight the combinations that are currently in clinical trials. Efforts to understand mechanisms of resistance are critical to advance the development of new targeted therapeutic strategies and further our understanding of the biological functions of BCL-2 in tumor cells.

16 December 2022 in Science Immunology
Verified
Journal Article
Closed access
GSGraeme P. Sullivan
Graeme P. Sullivan
PDPavel Davidovich
Pavel Davidovich
NMNatalia Muñoz-Wolf
Natalia Muñoz-Wolf
RWRoss W. Ward
Ross W. Ward
YSYasmina E. Hernandez Santana
Yasmina E. Hernandez Santana
SMSeamus J. Martin
Seamus J. Martin
Interleukin-1 (IL-1) family cytokines are key barrier cytokines that are typically expressed as inactive, or partially active, precursors that require proteolysis within their amino termini for activation. IL-37 is an enigmatic member of the IL-1 family that has been proposed to be activated by caspase-1 and to exert anti-inflammatory activity through engagement of the IL-18R and SIGIRR. However, here we show that the longest IL-37 isoform, IL-37b, exhibits robust proinflammatory activity upon amino-terminal proteolysis by neutrophil elastase or cathepsin S. In sharp contrast, caspase-1 failed to process or activate IL-37 at concentrations that robustly activated its canonical substrate, IL-1β. IL-37 and IL-36 exhibit high structural homology, and, consistent with this, a K53-truncated form of IL-37, mimicking the cathepsin S–processed form of this cytokine, was found to exert its proinflammatory effects via IL-36 receptor engagement and produced an inflammatory signature practically identical to IL-36. Administration of K53-truncated IL-37b intraperitoneally into wild-type mice also elicited an inflammatory response that was attenuated in IL-36R −/− animals. These data demonstrate that, in common with other IL-1 family members, mature IL-37 can also elicit proinflammatory effects upon processing by specific proteases.